GlassScriptPhysician profile
Barry K Mclean
NPI 1588634679
$24,491.90
in general payments reported to CMS, 2019-2025
63 companies · $1,408 in 2025
The $1,408 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $4,138 · 2020: $4,403 · 2021: $3,861 · 2022: $3,356 · 2023: $3,288 · 2024: $4,038 · 2025: $1,408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,304 · Consulting Fee: $2,430.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,303.82 |
| Consulting Fee | $2,430.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,949.99 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Roche Products Limited | $2,430.00 | 2024 | Xofluza |
| Lilly USA, LLC | $1,817.75 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $1,286.71 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $1,280.73 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $1,195.24 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $1,166.67 | 2021-2025 | |
| Abbvie INC. | $1,165.36 | 2020-2023 | |
| Esperion Therapeutics, INC. | $1,077.36 | 2020-2025 | Nexletol |
| Amarin Pharma, INC. | $1,030.46 | 2019-2022 | |
| Amgen INC. | $974.94 | 2019-2025 | Repatha, Repatha, Otezla |
| Sanofi-Aventis U.S. LLC | $827.49 | 2019-2023 | |
| Abbott Laboratories | $748.30 | 2019-2025 | Freestyle Libre |
| Kowa Pharmaceuticals America, INC. | $543.48 | 2019-2023 | Livalo |
| Dexcom, INC. | $497.17 | 2021-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $490.46 | 2019-2023 | Belsomra |
| Takeda Pharmaceuticals U.S.A., INC. | $471.91 | 2019-2023 | Trintellix |
| Novartis Pharmaceuticals Corporation | $467.10 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $449.37 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $358.35 | 2019-2024 | Veozah |
| Allergan, INC. | $339.71 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $328.21 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Corcept Therapeutics | $290.70 | 2021-2025 | Korlym |
| Antares Pharma, INC. | $229.88 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| Shield Therapeutics INC | $199.40 | 2022-2025 | Accrufer |
| Exact Sciences Corporation | $199.14 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $189.54 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $188.99 | 2019-2025 | Xifaxan |
| Azurity Pharmaceuticals, INC. | $157.96 | 2023 | Edarbyclor, Horizant |
| E.R. Squibb & Sons, L.L.C. | $136.28 | 2019-2023 | Eliquis |
| Halozyme INC | $105.35 | 2023 | |
| Boston Scientific Corporation | $104.49 | 2022-2025 | Wavewriter Alpha Prime 16, Infinion 16, Coveredge 32 |
| Arbor Pharmaceuticals, INC. | $101.37 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $93.06 | 2024-2025 | Voquezna |
| Mannkind Corporation | $86.30 | 2019 | |
| Medtronic, INC. | $65.38 | 2021-2025 | Minimed 780g |
| Tolmar, INC. | $63.78 | 2024-2025 | Jatenzo |
| Almatica Pharma LLC | $57.41 | 2021-2024 | Loreev Xr |
| Lifescan, INC. | $51.03 | 2021-2022 | |
| Medtronic Minimed, INC. | $45.08 | 2019 | |
| Idorsia Pharmaceuticals US INC | $42.38 | 2022-2024 | Quviviq |
| Paratek Pharmaceuticals, INC. | $30.44 | 2023 | Nuzyra |
| Pacira Therapeutics, INC. | $27.72 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $26.77 | 2023 | |
| Assertio Therapeutics, INC. | $25.55 | 2019 | |
| Ibsa Pharma INC. | $18.03 | 2022 | |
| Hikma Pharmaceuticals USA | $16.50 | 2019 | |
| Eisai INC. | $15.31 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $13.93 | 2020 | |
| Sumitomo Pharma America, INC. | $13.37 | 2024 | Gemtesa |
13 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5,500.93 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Mclean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.